Actively Recruiting
Evaluating Low-Dose Ketamine Infusion for Pain Relief in Children and Young Adults with Sickle Cell Disease During Vaso-occlusive Events
Led by Mohsen Saidinejad · Updated on 2026-09-02
120
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of ketamine at a low dose alongside standard pain medications to treat children and young adults aged 5 to 20 years with sickle cell disease who are experiencing vaso-occlusive pain events. The goal is to compare pain outcomes and medication needs between those receiving ketamine plus usual opioid treatment and those receiving only standard opioid care. This trial is a Phase 2 randomized study evaluating the safety and effectiveness of this approach. Participants will be randomly assigned to one of two groups one group receives an intravenous infusion of ketamine at 0.25 mgkg diluted in 100 milliliters of normal saline over 20 minutes, while the other group receives a placebo infusion of normal saline alone over the same duration. Both groups also receive standard opioid pain medication as part of their care. The treatments are delivered in a hospital setting during a vaso-occlusive pain episode requiring intravenous pain medication. During the study, participants will be closely monitored for opioid medication use required for pain relief over up to three days. Pain scores will be recorded at 30 and 60 minutes after treatment infusion. Additional outcomes tracked include emergency department length of stay, hospitalization rates within one month, and quality of life assessments conducted between 7 to 10 days and again 4 to 6 weeks after enrollment. Safety and response will be carefully evaluated throughout the study, which may last until April 2028.
CONDITIONS
Brief Title
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Research Team
C
Cynthia Luo, MD
M
Mohsen Saidinejad, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here